Proteosome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of NF-kappaB via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases

Details for Australian Patent Application No. 2002301611 (hide)

Owner Millennium Pharmaceuticals

Inventors Adams, Julian; Elliot, Peter; Plamondon, Louis

Agent Davies Collison Cave

Pub. Number AU-A-2002301611

Parent 95800

Filing date 22 October 2002

Wipo publication date 6 March 2003

International Classifications

A61K 031/69 - Boron compounds

A61K 031/40 - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

6 March 2003 Application Open to Public Inspection

  Published as AU-A-2002301611

11 December 2003 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002301612-Method for Transmitting Data From Server of Virtual Private Network to Mobile Node

2002301610-POPlife